Skip to content

APOTHEEK STEGEN

Active
Private limited companyfounded 1974active for 52 yearsAstridplein 37, 2280 Grobbendonk, BelgiumKBO/BCE: BE 0413.990.951

From the official registers: KBO 49 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

APOTHEEK STEGEN has been active since 1974 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €547,605 and a net result of €5,889. Equity has been stable since 2018 (±0.3% per year). Its solvency ranks better than 88% of 12,757 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow ReportCompare
APOTHEEK STEGENActiveChecked score 95/100
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 01-02-1974 Normal situation
Legal form
Private limited company
Registered office
Astridplein 37, 2280 Grobbendonk
Activity
Retail sale of pharmaceutical products NACE 47730and 1 other
Establishment unit
2.010.425.661 2280 Grobbendonk, since 01-02-1974
Financial year end
31 December
Peppol
Reachable since 04-12-2025
Company details

Board and ownership

Board
  • Lira Pharma BVDirector · since 01-01-2018
Shareholders
Board & ownership

Financial position

95 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts 2025
Gross margin
€164,085
▼ 39.0%
Turnover
≈ €770,000
estimated
Profit
€5,889
▼ 93.2%
Equity
€547,605
▲ 1.1%
Total assets
€701,156
▼ 5.4%
Staff
2 FTE
▼ 31.0%
2025 accounts filed 5 days after the deadline
Filed on 05-08-2026at the National Bank
Financials
Score breakdownraises riskSector: Retail trade (NACE 47)lowers riskLiquidity: current ratio 4.49, cash €178,268Equity €547,605 (78.1% of total assets)Founded in 1974Show the evidence

Checked score

Score 2025
95 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 63% of micro companies in retail trade (NACE 47)
Every signal that counts is listed under Signals.
Financial strength · tick: 2024
Strong
Solvency 100+2
equity 78.1% of total assets
Liquidity 74+1
short-term debt 21.9% · cash 25.4%
Profitability 51-32
return on assets 0.8%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,270 companies, NACE 47, micro)
Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: 0.1%▲ +0.1 percentage points vs 07-2025 09-2025: < 0.1%▼ -0.1 percentage points vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026lowest value 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: 0.1%▲ +0.1 percentage points vs 07-2026highest value 09-2026: < 0.1%▼ -0.1 percentage points vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026
Credit of up to €50,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 4.49 (3.64 in 2024), above the usual 1.5. Short-term debt is 21.9% and cash 25.4% of total assets. 21.9% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 92% of them on solvency, 80% on liquidity, 37% on profitability and 43% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises risk
lowers risk · Liquidity: current ratio 4.49, cash €178,268
NBB · annual accounts
lowers risk · Equity €547,605 (78.1% of total assets)
NBB · annual accounts
lowers risk · Founded in 1974
Companies that have existed this long fail less often. How much that weighs depends on the rest of the company's profile.
KBO
raises risk · Sector: Retail trade (NACE 47)
KBO
raises risk · 2025 accounts filed 5 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 05-08-2026, 5 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filings
Deviation from the deadline
2025
5 days late
2024
1 day early
2023
21 days late
2022
4 days early
2021
23 days late
2020
24 days late
2019
13 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 12 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 5 August (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Caution: Result fell in 2025from €85,989 to €5,889 ▼ 93.2% View
  • Positive: 3rd oldest company in Grobbendonk, Wholesale and retail trade sectorin the Checked rankings No. 3 View
  • Positive: 7 profitable years in a rowprofit 2025: €5,889 7 years View

Documents

Annual accounts at the NBB

All 49 annual accounts

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about APOTHEEK STEGEN

What is the company number of APOTHEEK STEGEN?
The company number of APOTHEEK STEGEN is 0413.990.951. The VAT number is the same number with BE in front: BE 0413.990.951.
Where is APOTHEEK STEGEN based?
The registered office is at Astridplein 37, 2280 Grobbendonk.Company details
What does APOTHEEK STEGEN do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of APOTHEEK STEGEN?
The legal form of APOTHEEK STEGEN is Private limited company (BV).
When was APOTHEEK STEGEN founded?
APOTHEEK STEGEN was founded on 01-02-1974.
Is APOTHEEK STEGEN still active?
Yes, APOTHEEK STEGEN is an active enterprise in the KBO register.
How many employees does APOTHEEK STEGEN have?
APOTHEEK STEGEN had an average of 2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of APOTHEEK STEGEN?
The turnover in financial year 2025 is ≈ €770,000. This figure is estimated from the gross margin of €164,085 and 51 comparable companies (NACE 477). It probably lies between €520,000 and €1.5m.
Is APOTHEEK STEGEN profitable?
In financial year 2025, APOTHEEK STEGEN made a profit of €5,889.
Where can I find the annual accounts of APOTHEEK STEGEN?
APOTHEEK STEGEN filed 49 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of APOTHEEK STEGEN due?
APOTHEEK STEGEN must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Companies linked to APOTHEEK STEGEN

Comparable companies

These companies have the same main activity as APOTHEEK STEGEN: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €554,000 and €792,000, founded between 1969 and 1987.

CompanyTotal assetsGross margin
APOTHEEK STEGEN Grobbendonk€701,156€164,085
Apotheek P. Hostens Antwerpen€738,383€205,352
MEER APOTHEEK Hoogstraten€705,802€168,352
PHARMACIE CRAHAY Chaudfontaine€618,494€161,018
Pharmacie TASSIN Beyne-Heusay€791,772€195,181
Pharmacie du progrès Charleroi€553,649€175,234
POELMAN Tessenderlo-Ham€709,941€179,864
Full comparison

Next steps

Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure